title: Role of uCyt+ in the detection and surveillance of urothelial carcinoma.
abstract: OBJECTIVE
  To test the clinical value and role of uCyt+ as a noninvasive tool for the detection and surveillance of urothelial carcinoma.
  
  
  METHODS
  Included in this prospective study were 235 patients (mean age 71.5 years, range 32 to 86). Of these, 98 patients had signs and symptoms suggestive of bladder cancer and 137 patients were being followed up after complete transurethral resection of superficial urothelial cancer (UC). All patients underwent urinary cytology and the uCyt+ test performed on ThinPrep (thin layer). All underwent subsequent cystoscopy and evaluation of any suspicious lesion by biopsy.
  
  
  RESULTS
  A total of 102 patients had histologically proven UC. In the group of patients with signs and symptoms suspicious of UC, the sensitivity of cytology increased from 5% for G1 to 84.6% for G3 tumors; for uCyt+, it was 85% for G1, 100% for G2, and 92.3% for G3 tumors. Combining cytology and uCyt+, the sensitivity was 85% for G1 and 100% for G2 and G3. In the group of follow-up patients, the sensitivity of cytology increased from 4.3% for G1 to 94.4% for G3 tumors; for uCyt+, it was 78.2% for G1, 70% for G2, and 94.4% for G3 tumors. Combining both tests, the sensitivity was 78.2% for G1, 90% for G2, and 100% for G3.
  
  
  CONCLUSIONS
  The uCyt+ is a valid test in the detection of UC of all grades and stages. It improves the sensitivity of cytology in low-grade tumors. The two tests combined may be a highly sensitive method to detect UC early in detection and surveillance.
authors.affiliation: Department of Urology and Pathology, General Hospital of Bolzano, Bolzano, Italy.
authors.forename: Michele
authors.initials: M
authors.lastname: Lodde
authors.forename: Christine
authors.initials: C
authors.lastname: Mian
authors.forename: Giovanni
authors.initials: G
authors.lastname: Negri
authors.forename: Lukas
authors.initials: L
authors.lastname: Berner
authors.forename: Nicola
authors.initials: N
authors.lastname: Maffei
authors.forename: Lukas
authors.initials: L
authors.lastname: Lusuardi
authors.forename: Salvatore
authors.initials: S
authors.lastname: Palermo
authors.forename: Michael
authors.initials: M
authors.lastname: Marberger
authors.forename: Clemens
authors.initials: C
authors.lastname: Brssner
authors.forename: Armin
authors.initials: A
authors.lastname: Pycha
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000652:urine*; D000912:Antibodies, Neoplasm / Q000652:urine*; D014408:Biomarkers, Tumor / Q000652:urine*; D002295:Carcinoma, Transitional Cell / Q000175:diagnosis* / Q000652:urine; D005455:Fluorescent Antibody Technique / Q000379:methods / Q000706:statistics & numerical data; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods / Q000706:statistics & numerical data; D008875:Middle Aged; D011237:Predictive Value of Tests; D012680:Sensitivity and Specificity; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000652:urine
chemical_list: D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D014408:Biomarkers, Tumor